Higher serum total bilirubin concentration is associated with lower risk of renal insufficiency in an adult population

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 10, 2015, Pages 19212-19222

  Lee, Ang Tse ^a   Wang, Ya Yu ^a,b,c   Lin, Shih Yi ^a,c   Liang, Jiin Tsae ^a   Sheu, Wayne Huey Herng ^a,c,d   Song, Yuh Min ^a   Chang, Wen Dau ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Bilirubin; Cardiovascular disease; Chronic kidney disease; Kidney function

Indexed keywords

BILIRUBIN;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MIDDLE AGED; RISK FACTOR;

EID: 84949674292     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F and Garg AX. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034-2047.
2. Go AS, Chertow GM, Fan D, McCulloch CE and Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F and Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
4. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A and Matsuo S. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009; 13: 621-630.
5. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X and Wang H. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012; 379: 815-822.
6. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, Chiang PH, Hsu CC, Sung PK, Hsu YH and Wen SF. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008; 371: 2173-2182.
7. Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey AS, Salem D, Sarnak MJ and Weiner DE. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007; 167: 1130-1136.
8. Sinha SK, Shaheen M, Rajavashisth TB, Pan D, Norris KC and Nicholas SB. Association of race/ethnicity, inflammation, and albuminuria in patients with diabetes and early chronic kidney disease. Diabetes Care 2014; 37: 1060-1068.
9. Tian N, Penman AD, Manning RD Jr, Flessner MF and Mawson AR. Association between circulating specific leukocyte types and incident chronic kidney disease: the Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Hypertens 2012; 6: 100-108.
10. Wu TW, Fung KP, Wu J, Yang CC and Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 1996; 51: 859-862.
11. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN and Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-1046.
12. Mazzone GL, Rigato I, Ostrow JD, Bossi F, Bortoluzzi A, Sukowati CH, Tedesco F and Tiribelli C. Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun 2009; 386: 338-344.
13. Schwertner HA, Jackson WG and Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994; 40: 18-23.
14. Schwertner HA and Fischer JR Jr. Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease. Atherosclerosis 2000; 150: 381-387.
15. Kimm H, Yun JE, Jo J and Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 2009; 40: 3422-3427.
16. Perlstein TS, Pande RL, Beckman JA and Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol 2008; 28: 166-172.
17. Djoussé L, Rothman KJ, Cupples LA, Levy D and Ellison RC. Effect of serum albumin and bilirubin on the risk of myocardial infarction (the Framingham Offspring Study). Am J Cardiol 2003; 91: 485-488.
18. Tanaka M, Fukui M, Okada H, Senmaru T, Asano M, Akabame S, Yamazaki M, Tomiyasu K, Oda Y, Hasegawa G, Toda H and Nakamura N. Low serum bilirubin concentration is a predictor of chronic kidney disease. Atherosclerosis 2014; 234: 421-425.
19. Ryu S, Chang Y, Zhang Y, Woo HY, Kwon MJ, Park H, Lee KB, Son HJ, Cho J and Guallar E. Higher serum direct bilirubin levels were associated with a lower risk of incident chronic kidney disease in middle aged Korean men. PLoS One 2014; 9: e75178.
20. Fukui M, Tanaka M, Shiraishi E, Harusato I, Hosoda H, Asano M, Hasegawa G and Nakamura N. Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int 2008; 74: 1197-1201.
21. Targher G, Bosworth C, Kendrick J, Smits G, Lippi G and Chonchol M. Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Clin Chem Lab Med 2009; 47: 1055-1062.
22. Targher G, Zoppini G, Cesare Guidi G and Lippi G. Relationship between serum bilirubin and kidney function in non-diabetic and diabetic individuals. Kidney Int 2009; 75: 863.
23. Tsai WN, Wang YY, Liang JT, Lin SY, Sheu WH and Chang WD. Serum total bilirubin concentrations are inversely associated with total white blood cell counts in an adult population. Ann Clin Biochem 2015; 52: 251-8.
24. Wang F, Ye P, Luo L, Xiao W and Wu H. Association of risk factors for cardiovascular disease and glomerular filtration rate: a community-based study of 4,925 adults in Beijing. Nephrol Dial Transplant 2010; 25: 3924-3931.
25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T and Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
26. Han SS, Na KY, Chae DW, Kim YS, Kim S and Chin HJ. High serum bilirubin is associated with the reduced risk of diabetes mellitus and diabetic nephropathy. Tohoku J Exp Med 2010; 221: 133-140.
27. Kawamoto R, Ninomiya D, Hasegawa Y, Kasai Y, Kusunoki T, Ohtsuka N and Kumagi T. Association between serum bilirubin and estimated glomerular filtration rate among elderly persons. PLoS One 2014; 9: e115294.
28. Boon AC, Bulmer AC, Coombes JS and Fassett RG. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Renal Physiol 2014; 307: F123-136.
29. Baranano DE, Rao M, Ferris CD and Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A 2002; 99: 16093-16098.
30. Kang SJ, Lee C and Kruzliak P. Effects of serum bilirubin on atherosclerotic processes. Ann Med 2014; 46: 138-147.
31. Kao MP, Ang DS, Pall A and Struthers AD. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens 2010; 24: 1-8.
32. Dullaart RP, de Vries R and Lefrandt JD. Increased large VLDL and small LDL particles are related to lower bilirubin in Type 2 diabetes mellitus. Clin Biochem 2014; 47: 170-175.
33. Lee MJ, Jung CH, Kang YM, Hwang JY, Jang JE, Leem J, Park JY, Kim HK and Lee WJ. Serum bilirubin as a predictor of incident metabolic syndrome: a 4-year retrospective longitudinal study of 6205 initially healthy Korean men. Diabetes Metab 2014; 40: 305-309.
34. Cheriyath P, Gorrepati VS, Peters I, Nookala V, Murphy ME, Srouji N and Fischman D. High Total Bilirubin as a Protective Factor for Diabetes Mellitus: An Analysis of NHANES Data From 1999-2006. J Clin Med Res 2010; 2: 201-206.
35. Jung CH, Lee MJ, Kang YM, Hwang JY, Jang JE, Leem J, Park JY, Kim HK and Lee WJ. Higher serum bilirubin level as a protective factor for the development of diabetes in healthy Korean men: a 4 year retrospective longitudinal study. Metabolism 2014; 63: 87-93.
36. Ohnaka K, Kono S, Inoguchi T, Yin G, Morita M, Adachi M, Kawate H and Takayanagi R. Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res Clin Pract 2010; 88: 103-110.
37. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
38. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliðadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K and Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11: e1001680.
39. Salomone F, Li Volti G, Rosso C, Grosso G and Bugianesi E. Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis. J Gastroenterol Hepatol 2013; 28: 1202-1208.
40. Noborisaka Y, Ishizaki M, Yamada Y, Honda R, Yokoyama H, Miyao M and Tabata M. Distribution of and factors contributing to chronic kidney disease in a middle-aged working population. Environ Health Prev Med 2013; 18: 466-476.
41. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ and Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; 342: d671.
42. Schwertner HA. Association of smoking and low serum bilirubin antioxidant concentrations. Atherosclerosis 1998; 136: 383-387.
43. McCarty MF. “Iatrogenic Gilbert syndrome”--a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007; 69: 974-994.
44. McCarty MF. Serum bilirubin may serve as a marker for increased heme oxygenase activity and inducibility in tissues--a rationale for the versatile health protection associated with elevated plasma bilirubin. Med Hypotheses 2013; 81: 607-610.
45. Botros FT, Schwartzman ML, Stier CT Jr, Goodman AI and Abraham NG. Increase in heme oxygenase-1 levels ameliorates renovascular hypertension. Kidney Int 2005; 68: 2745-2755.
46. Dekker D, Dorresteijn MJ, Pijnenburg M, Heemskerk S, Rasing-Hoogveld A, Burger DM, Wagener FA and Smits P. The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2011; 31: 458-463.
47. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R and Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19: 2407-2413.
48. Jo J, Yun JE, Lee H, Kimm H and Jee SH. Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population. Endocrine 2011; 39: 182-189.
49. Levin A and Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 2014; 85: 49-61.